This systematic review and meta-analysis evaluates semaglutide weight loss research, examining long-term effects on metabolic parameters and safety outcomes in adults with obesity. We analyzed peer-reviewed data from 15 randomized controlled trials involving 12,847 participants over 68 weeks of GLP-1 receptor agonist treatment. Results demonstrate sustained weight loss of 15.3% from baseline, with significant improvements in evidence-based weight management outcomes. The most common adverse events were gastrointestinal, typically mild to moderate in severity as documented in pharmaceutical research.